Liothyronine sustained-release

Drug Profile

Liothyronine sustained-release

Alternative Names: BCT-303; Liothyronine sodium; Sustained-release liothyronine sodium; Sustained-release T3; Thyromax; TriThroid

Latest Information Update: 21 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ITL Pharma
  • Developer IPE
  • Class Amino acids; Small molecules; Thyronines
  • Mechanism of Action Thyroid hormone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Hypothyroidism

Most Recent Events

  • 20 Feb 2017 ITL Pharma has patent protection for TriThroid® in USA
  • 18 Apr 2016 Phase-II development is ongoing in USA
  • 01 Jul 2014 IPE completes a phase II trial in Hypothyroidism in USA (NCT01800617)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top